Plain-English translation of ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called V-IMMUNE, which is an immunoglobulin therapy designed to replace missing or low antibodies in people with primary immunodeficiencies. The medication is given as an intravenous infusion every 3 weeks. Researchers are studying whether this treatment is safe and effective for patients whose bodies cannot produce enough antibodies on their own.
Many people with primary immunodeficiencies have very low levels of protective antibodies, making them vulnerable to serious infections. While other immunoglobulin treatments exist, researchers are testing this medication to see if it offers a better option for patients who may not be responding well to their current therapy.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the medication V-IMMUNE as an intravenous infusion every 3 weeks. Before each infusion, you will receive some pre-medications to help prevent side effects. Each infusion takes 3 to 6 hours, and the infusion rate starts slowly and gradually increases if you tolerate it well. You will be monitored throughout the infusion and afterward to watch for any reactions or side effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Brazil